Revvity, 62BDAPEH, HTRF EPIgeneous Binding Domain A Detection Kit, 10,000 Assay Points

Overview
The EPIgeneous Binding Domain kit series provides a simple biochemical approach to study epigenetic reader domain interactions with modified histones. All kits are based on a GST-tagged binding domain / biotin-coupled Histone peptide format, and can be run using the same add-and-read single plate protocol.
Binding Domain kit A has been successfully validated on 4 different domains, including some important therapeutic targets, in the BRD family.
HTRF assays offer many advantages over other technologies:

Homogeneous add-and-read format
No wash steps
Low background
Straightforward miniaturization from 96- or 384-well microplates to high density assay formats such as 384-well low volume and 1536-well plates
Stable signal, providing flexibility in time of readout or size of assays
How it works
Assay principle
In EPIgeneous Binding Domain kit A, the GST-tagged reader domain protein binding to the biotinylated peptide substrate is detected by a conjugate mix: anti-GST Eu cryptate-labeled antibody conjugate (donor), and d2-conjugated streptavidin (acceptor). The interaction of the reader domain with the substrate brings the donor and acceptor dyes into close proximity, and allows FRET to occur upon light excitation. The specific signal at 665 nm is inhibited when a specific compound prevents the reader domain protein from binding to its substrate. Application-Biochemical Enzymatic Assay
Brand-EPIgeneous
Detection Modality-HTRF
Product Group-Kit
Sample Volume-120 µL
Shipping Conditions-Shipped in Dry Ice
Target Class-Epigenetics
Technology-TR-FRET
Therapeutic Area-Metabolism/Diabetes Neuroscience Oncology & Inflammation
Unit Size-10,000 assay points